ID A1AT_HUMAN; STANDARD; 2DG.
AC P01009;
DT 01-AUG-1993, integrated into SWISS-2DPAGE (release 0).
DT 15-MAY-2003, 2D annotation version 1.
DT 19-MAY-2011, general annotation version 18.
DE RecName: Full=Alpha-1-antitrypsin; AltName: Full=Alpha-1 protease
DE inhibitor; AltName: Full=Alpha-1-antiproteinase; AltName: Full=Serpin A1;
DE Contains: RecName: Full=Short peptide from AAT; Short=SPAAT; Flags: Precursor;.
GN Name=SERPINA1; Synonyms=AAT, PI; ORFNames=PRO0684, PRO2209;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini;
OC Hominidae; Homo.
OX NCBI_TaxID=9606;
MT CSF_HUMAN, HEPG2SP_HUMAN, LIVER_HUMAN, LYMPHOMA_HUMAN, PLASMA_HUMAN.
IM CSF_HUMAN, HEPG2SP_HUMAN, LIVER_HUMAN, LYMPHOMA_HUMAN, PLASMA_HUMAN.
RN [1]
RP MAPPING ON GEL.
RX MEDLINE=93162045; PubMed=1286669;
RA Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R., Appel
RA R.D., Hughes G.J.;
RT ''''''Human liver protein map: a reference database established by
RT microsequencing and gel comparison'';'';'';
RL Electrophoresis 13(1):992-1001(1992).
RN [2]
RP PATHOLOGICAL LEVEL.
RA Allen R.C., Bienvenu J., Laurent P., Suskind R.M.;
RL (IN) Robert C. Allen, et al. (eds.);
RL Marker proteins in inflammation: proceedings of the symposium, Lyon,
RL France, April 1981, pp.0-0, W. de Gruyter, Berlin (1982).
RN [3]
RP PATHOLOGICAL VARIANTS.
RA Sharp H.L.;
RL (IN) McKusick V.A., Clairbone R. (eds.);
RL Medical genetics, pp.131-140, H. P. Publ. Co. Inc., New York (1973).
RN [4]
RP GENETIC VARIANTS.
RX MEDLINE=80181048; PubMed=6102963;
RA Cox D.W., Johnson A.M., Fagerhol M.K.;
RT ''''''Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978'';'';'';
RL Hum. Genet. 53(1):429-433(1980).
RN [5]
RP PATHOLOGICAL VARIANTS.
RX MEDLINE=83297520; PubMed=6604220;
RA Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W.;
RT ''''''Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin
RT Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder'';'';'';
RL New Engl. J. Med. 309(1):694-698(1983).
RN [6]
RP MAPPING ON GEL.
RX MEDLINE=93092937; PubMed=1459097;
RA Hughes G.J., Frutiger S., Paquet N., Ravier F., Pasquali C., Sanchez
RA J.-C., James R.W., Tissot J.-D., Bjellqvist B., Hochstrasser D.F.;
RT ''''''Plasma protein map: an update by microsequencing'';'';'';
RL Electrophoresis 13(1):707-714(1992).
RN [7]
RP MAPPING ON GEL.
RX MEDLINE=96007934; PubMed=7498157;
RA Sanchez J.-C., Appel R.D., Golaz O.G., Pasquali C., Ravier F., Bairoch
RA A., Hochstrasser D.F.;
RT ''''''Inside SWISS-2DPAGE database'';'';'';
RL Electrophoresis 16(1):1131-1151(1995).
CC -!- SUBUNIT: SINGLE CHAIN
2D -!- MASTER: CSF_HUMAN;
2D -!- PI/MW: SPOT 2D-000BG6=4.94/132121;
2D -!- PI/MW: SPOT 2D-000BGA=5.00/132770;
2D -!- PI/MW: SPOT 2D-000BGH=5.06/130832;
2D -!- PI/MW: SPOT 2D-000BTP=4.78/60493;
2D -!- PI/MW: SPOT 2D-000BTU=4.83/59122;
2D -!- PI/MW: SPOT 2D-000BU8=4.90/57782;
2D -!- PI/MW: SPOT 2D-000BUC=4.79/58523;
2D -!- PI/MW: SPOT 2D-000BUV=4.96/57051;
2D -!- PI/MW: SPOT 2D-000BV7=5.04/56473;
2D -!- PI/MW: SPOT 2D-000BVN=5.08/56043;
2D -!- PI/MW: SPOT 2D-000BVO=5.12/57051;
2D -!- PI/MW: SPOT 2D-000BWW=5.15/55193;
2D -!- MAPPING: MATCHING WITH THE PLASMA MASTER GEL [7].
2D -!- MASTER: HEPG2SP_HUMAN;
2D -!- PI/MW: SPOT 2D-0008W1=4.62/57821;
2D -!- PI/MW: SPOT 2D-0008WN=4.69/55230;
2D -!- PI/MW: SPOT 2D-0008WS=4.74/54511;
2D -!- PI/MW: SPOT 2D-0008WZ=4.80/53979;
2D -!- PI/MW: SPOT 2D-0008YD=4.87/52240;
2D -!- PI/MW: SPOT 2D-0008YS=4.95/51391;
2D -!- PI/MW: SPOT 2D-0008YY=5.04/51223;
2D -!- PI/MW: SPOT 2D-0008Z4=5.12/51223;
2D -!- MAPPING: MATCHING WITH THE PLASMA MASTER GEL [7].
2D -!- MASTER: LIVER_HUMAN;
2D -!- PI/MW: SPOT 2D-0000LY=4.92/56382;
2D -!- PI/MW: SPOT 2D-0000MB=4.97/55609;
2D -!- PI/MW: SPOT 2D-0000MX=5.01/54544;
2D -!- PI/MW: SPOT 2D-0000NT=5.08/53944;
2D -!- DISEASE POSITIONAL VARIANTS: ALPHA-1-ANTITRYPSIN PITTSBURGH [5].
2D -!- NORMAL POSITIONAL VARIANTS: 30 GENETIC VARIANTS KNOWN AS PI ALLELES [4].
2D -!- PATHOLOGICAL LEVEL: DECREASED DURING HEPATIC CIRRHOSIS IN CHILDREN
2D [3] AND EMPHYSEMA; INCREASED DURING THE ACUTE-PHASE REACTION [2], LIVER
2D DAMAGE AND PREGNANCY.
2D -!- MAPPING: MATCHING WITH A PLASMA GEL [1].
2D -!- MASTER: LYMPHOMA_HUMAN;
2D -!- PI/MW: SPOT 2D-0007GG=4.87/55663;
2D -!- PI/MW: SPOT 2D-0007H1=4.92/54763;
2D -!- PI/MW: SPOT 2D-0007HH=5.00/53878;
2D -!- PI/MW: SPOT 2D-0007HT=5.08/53503;
2D -!- MAPPING: MATCHING WITH THE LIVER MASTER GEL [7].
2D -!- MASTER: PLASMA_HUMAN;
2D -!- PI/MW: SPOT 2D-0004B2=5.01/108882;
2D -!- PI/MW: SPOT 2D-0004B8=5.05/106590;
2D -!- PI/MW: SPOT 2D-0004KJ=5.11/69340;
2D -!- PI/MW: SPOT 2D-0004QH=4.91/57706;
2D -!- PI/MW: SPOT 2D-0004QK=4.87/57549;
2D -!- PI/MW: SPOT 2D-0004QS=4.95/56773;
2D -!- PI/MW: SPOT 2D-0004R9=5.00/56313;
2D -!- PI/MW: SPOT 2D-0004RF=4.91/56466;
2D -!- PI/MW: SPOT 2D-0004RM=4.87/56313;
2D -!- PI/MW: SPOT 2D-0004RW=5.05/55856;
2D -!- PI/MW: SPOT 2D-0004SF=4.91/55252;
2D -!- PI/MW: SPOT 2D-0004SO=4.95/54953;
2D -!- PI/MW: SPOT 2D-0004SQ=5.00/54953;
2D -!- PI/MW: SPOT 2D-0004SZ=5.05/54507;
2D -!- PI/MW: SPOT 2D-0004TO=4.95/54065;
2D -!- PI/MW: SPOT 2D-0004TP=4.99/53626;
2D -!- PI/MW: SPOT 2D-0004TU=5.10/53626;
2D -!- PI/MW: SPOT 2D-0004TW=5.04/53336;
2D -!- PI/MW: SPOT 2D-0004WJ=4.87/50380;
2D -!- PI/MW: SPOT 2D-0004WZ=4.91/49297;
2D -!- PI/MW: SPOT 2D-0004X0=4.95/49431;
2D -!- PI/MW: SPOT 2D-0004XH=4.99/48369;
2D -!- NORMAL LEVEL: 1900-3500 MG/L.
2D -!- PATHOLOGICAL LEVEL: DECREASED DURING HEPATIC CIRRHOSIS IN CHILDREN
2D [3] AND EMPHYSEMA; INCREASED DURING THE ACUTE-PHASE REACTION [2], LIVER
2D DAMAGE AND PREGNANCY.
2D -!- POSITIONAL VARIANTS: 30 GENETIC VARIANTS KNOWN AS PI ALLELES [4].
2D -!- MAPPING: MICROSEQUENCING [6].
CC ---------------------------------------------------------------------------
CC This SWISS-2DPAGE entry is copyright the Swiss Institute of Bioinformatics.
CC There are no restrictions on its use by non-profit institutions as long as
CC its content is in no way modified and this statement is not removed.
CC Usage by and for commercial entities requires a license agreement (See
CC http://world-2dpage.expasy.org/swiss-2dpage/docs/license.html or send email from legal@sib.swiss).
CC ---------------------------------------------------------------------------
DR DOSAC-COBS 2D-PAGE; P01009; P01009.
DR DOSAC-COBS-2DPAGE; P01009; A1AT_HUMAN.
DR HSC-2DPAGE; P01009; HUMAN.
DR OGP-WWW; P01009.
DR REPRODUCTION-2DPAGE; P01009; P01009.
DR REPRODUCTION-2DPAGE; IPI00553177; IPI00553177.
DR Siena-2DPAGE; P01009; A1AT_HUMAN.
DR UCD-2DPAGE; P01009; A1AT_HUMAN.
DR UniProtKB/Swiss-Prot; P01009; A1AT_HUMAN.
//